Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.30 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574378 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3GABRR1KDM1A | |
| SCHEMBL21777886 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3GABRR1KDM1A | |
| SCHEMBL21777884 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3GABRR1KDM1A | |
| SCHEMBL3528773 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3GABRR1KDM1A | |
| SCHEMBL3875618 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3GABRR1KDM1A | |
| SCHEMBL25430032 | 1.00 | CHRM2 (0.33) | CHRM2CHRM1CHRM3GABRR1KDM1A | |
| SCHEMBL22283970 | 0.91 | ALDH1A1 (0.33) | CHRM2CHRM1CHRM3GABRR1 | |
| SCHEMBL19520745 | 0.91 | ALDH1A1 (0.33) | CHRM2CHRM1CHRM3GABRR1 | |
| SCHEMBL23091621 | 0.91 | ALDH1A1 (0.33) | CHRM2CHRM1CHRM3GABRR1 | |
| SCHEMBL15900199 | 0.91 | ALDH1A1 (0.33) | CHRM2CHRM1CHRM3GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112074511-B | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-04-26 | — | — | CN | disclosed |
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-04-11 | — | — | US | disclosed |
| WO-2024053650-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST DIACYLGLYCEROL KINASE α AND/OR ζ, AND PHARMACEUTICAL USE THEREOF | 小野薬品工業株式会社 | 2024-03-14 | — | — | WO | disclosed |
| EP-4302834-A2 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3484856-B1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116478132-A | 2, 5-disubstituted and 2,5, 6-trisubstituted 3-methylpyrazines as allosteric SHP2 inhibitors | 锐新医药公司 | 2023-07-25 | — | — | CN | disclosed |
| WO-2023135508-A1 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2023-07-20 | — | — | WO | disclosed |
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| CN-115485023-A | Compounds and methods for modulating splicing | 雷密克斯医疗公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20050131011-A1 | Chemical compounds | PFIZER, INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050107424-A1 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-6855724-B2 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1492789-A1 | TROPANE DERIVATIVES AS CCR5 MODULATORS | Pfizer Limited (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040014742-A1 | Antiinflammatory agents; viricides | PFIZER INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003084954-A1 | TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LIMITED (GB) | 2003-10-16 | — | — | WO | disclosed |
| US-6586430-B1 | Administering azabicyclo compounds to treat human immunodeficiency virus infections and respiratory system disorders | PFIZER INC. | 2003-07-01 | — | — | US | disclosed |
| US-6531484-B2 | Viricides for preventing infection by HIV, treating infection by HIV, delaying of the onset of AIDS, or treating AIDS | MERCK & CO., INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020198178-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116878-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | CHRM2 3889/4885CHRM1 4408/4885CHRM3 3658/4885 |
| US-11661401-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN22, PTPN2 | CHRM2 3114/4885CHRM1 3241/4885CHRM3 3279/4885 |
| US-20040014742-A1 | Antiinflammatory agents; viricides | CCR5, CXCR1, CCR1 | CHRM2 422/4885CHRM1 251/4885CHRM3 464/4885 |
| US-20050107424-A1 | Tropane derivatives useful in therapy | CCR5, CXCR4, CX3CR1 | CHRM2 50/4885CHRM1 53/4885CHRM3 55/4885 |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | CHRM2 4778/4885CHRM1 4768/4885CHRM3 4812/4885 |
| US-20020198178-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CCL5 | CHRM2 305/4885CHRM1 191/4885CHRM3 395/4885 |
| US-20050131011-A1 | Chemical compounds | CCR5, CCR2, CX3CR1 | CHRM2 417/4885CHRM1 392/4885CHRM3 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.